TCR Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight's "TCR Therapy Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TCR Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the TCR Therapy Pipeline. Dive into DelveInsight's comprehensive report today! @ TCR Therapy Pipeline Outlook [https://www.delveinsight.com/sample-request/tcr-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the TCR Therapy Pipeline Report

* On August 19, 2025, Christian Hinrichs initiated a study to evaluate the feasibility of administering a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) for locoregionally advanced HPV-associated cancers. The primary objective of the E7 TCR-T cell therapy is to shrink or eliminate tumors, thereby facilitating definitive treatment and improving overall survival.
* On August 12, 2025, BlueSphere Bio Inc. announced a clinical trial to investigate BSB-1001, a novel cellular therapy for the treatment of blood cancers, including AML, ALL, and MDS. The trial is designed to assess the safety of BSB-1001 and to determine its potential effectiveness in preventing cancer relapse.
* DelveInsight's TCR Therapy Pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for TCR Therapy treatment.
* The leading TCR Therapy Companies such as Immunocore, Guangdong Xiangxue Precision Medical Technology, Altimmune, Immatics, TScan Therapeutics, SCG Cell Therapy, Treadwell Therapeutics, Adaptimmune, Immatics N.V. and others.
* Promising TCR Therapy Pipeline Therapies such as Fludarabine, Aldesleukin, Blinatumomab, Cyclophosphamide, Tebentafusp, Cisplatin, Gemcitabine, ALT-801 and others.

Get insights into TCR Therapy Clinical Trials, emerging therapies, and leading companies with DelveInsight @ TCR Therapy Treatment Drugs [https://www.delveinsight.com/sample-request/tcr-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

TCR Therapy Emerging Drugs Profile

* Brenetafusp: Immunocore

IMC-F106C is an ImmTAC targeting PRAME for patients with HLA-A02, which is expressed in approximately 40% of Western populations (United States, Canada, EU). In order to expand the potential of TCR therapy targeting PRAME, the Company is developing IMC-T119C, a first-in-class ImmTAC product candidate targeting a PRAME peptide presented by HLA-A24. HLA-24 is an HLA-type that is estimated to be present in 60% of people in Japan and 15-20% in Western populations. Currently the drug is in Phase III stage of clinical trial evaluation for the treatment of patients with 1L advanced, cutaneous melanoma.

* Pemvidutide - Altimmune

Pemvidutide (proposed INN, formerly known as ALT-801) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. By combining GLP-1 and glucagon activity in a single peptide, pemvidutide has the potential to achieve weight loss comparable to bariatric surgery. Pemvidutide also has been shown to increase the breakdown of fat and its mobilization within the liver, which may have beneficial effects on insulin resistance, a common problem in people with obesity. Pemvidutide incorporates the EuPortTM domain, a proprietary technology that increases its serum half-life for weekly dosing while slowing the entry of pemvidutide into the bloodstream, which may improve its tolerability. In a Phase I clinical study, pemvidutide demonstrated striking reductions in body weight, liver fat and serum lipids. Currently the drug is in Phase II stage of its development for the treatment of NASH.

* TSC 101: TScan Therapeutics

TSC-101 is the first clinical cell therapy product targeting minor histocompatibility antigen HA-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation. TSC-101 is an investigational T cell receptor-engineered T cell therapy (TCR-T) developed by TScan Therapeutics, targeting the minor histocompatibility antigen HA-2. It is designed to eliminate residual disease and prevent relapse in patients with hematologic malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL), following allogeneic hematopoietic cell transplantation (HCT). Currently, the drug is in Phase I trial for the treatment of hematologic malignancies.

The TCR Therapy Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of TCR Therapy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for TCR Therapy Treatment.
* TCR Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* TCR Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the TCR Therapy market

Explore groundbreaking therapies and clinical trials in the TCR Therapy Pipeline. Access DelveInsight's detailed report now! @ New TCR Therapy Drugs [https://www.delveinsight.com/sample-request/tcr-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

TCR Therapy Companies

Immunocore, Guangdong Xiangxue Precision Medical Technology, Altimmune, Immatics, TScan Therapeutics, SCG Cell Therapy, Treadwell Therapeutics, Adaptimmune, Immatics N.V. and others.

TCR Therapy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

TCR Therapy Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ TCR Therapy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/tcr-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the TCR Therapy Pipeline Report

* Coverage- Global
* TCR Therapy Companies- Immunocore, Guangdong Xiangxue Precision Medical Technology, Altimmune, Immatics, TScan Therapeutics, SCG Cell Therapy, Treadwell Therapeutics, Adaptimmune, Immatics N.V. and others.
* TCR Therapy Pipeline Therapies- Fludarabine, Aldesleukin, Blinatumomab, Cyclophosphamide, Tebentafusp, Cisplatin, Gemcitabine, ALT-801 and others.
* TCR Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* TCR Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth TCR Therapy Pipeline report today! @ TCR Therapy Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/tcr-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* TCR-Therapy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* TCR-Therapy - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* IMC F106C: Immunocore
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Pemvidutide - Altimmune
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* TSC-100: TScan Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* TCR-Therapy Key Companies
* TCR-Therapy Key Products
* TCR-Therapy- Unmet Needs
* TCR-Therapy- Market Drivers and Barriers
* TCR-Therapy- Future Perspectives and Conclusion
* TCR-Therapy Analyst Views
* TCR-Therapy Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tcr-therapy-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/tcr-therapy-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.